To determine the mechanisms underlying MPNST response to CDK4/6-MEK inhibitor therapy, gene expression profiling of drug sensitive versus drug resistant tumors was performed [14]. The gene discussed is MAP2K7; the disease is malignant peripheral nerve sheath tumor.